AS2034178 --- GPR40 Agonist


Catalog No. size PriceQuantity
M60221-2S 2 mg solid $139
M60221-10S 10mg solid $563

Description

AS2034178 is the potent, selective and orally bioavailable GPR40 (FFA1) agonist. It has good selectivity for over GPR41, GPR43, GPR119, GPR120 and PPARγ. It can Induce glucose-dependent insulin secretion in pancreatic MIN6 cells and in vivo. AS2034178 could decrease plasma glucose and HbA1c levels after repeat administration to ob/ob mice, with favorable oral absorption and pharmacokinetics. Repeat administration of AS2034178 enhanced insulin sensitivity in an insulin tolerance test and a euglycemic-hyperinsulinemic clamp test.

Product information

CAS Number: 1030846-42-4

Molecular Weight: 448.53

Formula: C27H29FN2O3

Chemical Name: 3-(2-fluoro-4-(((1-(2-phenoxyethyl)-1,2,3,4-tetrahydroquinolin-5-yl)methyl)amino)phenyl)propanoic acid

Smiles: OC(=O)CCC1=CC=C(C=C1F)NCC1=CC=CC2=C1CCCN2CCOC1C=CC=CC=1

InChiKey: VENOXIKBBUVHRY-UHFFFAOYSA-N

InChi: InChI=1S/C27H29FN2O3/c28-25-18-22(13-11-20(25)12-14-27(31)32)29-19-21-6-4-10-26-24(21)9-5-15-30(26)16-17-33-23-7-2-1-3-8-23/h1-4,6-8,10-11,13,18,29H,5,9,12,14-17,19H2,(H,31,32)

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO up to 50 mM

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

AS2034178 was used at 1-10 µM final concentration in various in vitro assays.

In Vivo:

AS2034178 was dosed to normal mice and Zucker fatty rats under fasting conditions for oral glucose tolerance test via oral gavage at 3-10 mg/kg. It was dosed to diabetic ob/ob mice via oral gavage at 3-30 mg/kg once per day for 2 weeks.

References:

  1. Tanaka H, et al. Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion. (2013) J Pharmacol Exp Ther. 346(3):443-52.

Products are for research use only. Not for human use.


Documents

Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed